Overall, median PFS was significantly improved by several months in the ICT group versus the control group. 후속 조사가 계속 진행 중이며 몇몇 하위 그룹에서는 아직 중앙 생존 기간에 도달하지 못했습니다. The outcomes for MGMT methylated, HLAA positive patients appear particularly positive.